Detectable HIV-RNA Viral Load Among HIV-Infected Pregnant Women on Treatment in Northern Uganda

Authors

  • Agnes Napyo, MPH Department of Public Health, Faculty of Health Sciences, Busitema University, 236 Tororo, Uganda; Centre for International Health, University of Bergen, 7804 Bergen, Norway; Department of Pediatrics and Child Health, Makerere University, 7062 Kampala, Uganda
  • James K Tumwine, PhD Department of Pediatrics and Child Health, Makerere University, 7062 Kampala, Uganda
  • David Mukunya, PhD Centre for International Health, University of Bergen, 7804 Bergen, Norway
  • Josephine Tumuhamye, MSc Centre for International Health, University of Bergen, 7804 Bergen, Norway
  • Anna Agnes Ojok Arach, MPH Department of Pediatrics and Child Health, Makerere University, 7062 Kampala, Uganda; Department of Nursing, Lira University, 1035 Lira, Uganda
  • Grace Ndeezi, PhD Department of Pediatrics and Child Health, Makerere University, 7062 Kampala, Uganda
  • Paul Waako, PhD Department of Pharmacology, Faculty of Health Sciences, Busitema University, 236 Tororo, Uganda
  • Thorkild Tylleskär, PhD Centre for International Health, University of Bergen, 7804 Bergen, Norway

DOI:

https://doi.org/10.21106/ijma.374

Keywords:

HIV , Women , Pregnancy , Pregnant women, Viral load, Viral suppression, PMTCT , Antiretroviral therapy, Uganda

Abstract

Background / Objectives: Detectable HIV viral load among HIV-infected pregnant women remains a public health threat. We aimed to determine factors associated with detectable viral load among HIV-infected pregnant women in Lira, Northern Uganda.

Methods: We conducted a cross-sectional survey among 420 HIV-infected pregnant women attending Lira Regional Referral Hospital using a structured questionnaire and combined it with viral load tests from Uganda National Health Laboratories. We conducted multivariable logistic regression while adjusting for confounders to determine the factors associated with detectable viral load and we report adjusted odds ratios and proportion of women with viral load less than 50 copies/ml and above 1000 copies, respectively.

Results: The prevalence of detectable viral load (>50 copies/ml) was 30.7% (95%CI: 26.3% - 35.4%) and >1000 copies/ml was 8.1% (95% CI: 5.7% – 11.1%). Factors associated with detectable viral load were not belonging to the Lango ethnicity (adjusted odds ratio = 1.92, 95%CI: 1.05 – 3.90) and taking a second-line (protease inhibitor-based) regimen (adjusted odds ratio = 4.41, 95%CI: 1.13 – 17.22).

Conclusions and Global Health Implications: HIV-infected pregnant women likely to have detectable viral load included those taking a protease inhibitor-based regimen and those who were not natives of Lira. We recommend intensified clinical and psychosocial monitoring for medication compliance among HIVinfected pregnant women that are likely to have a detectable viral load to significantly lower the risk of vertical transmission of HIV in Lira specifically those taking a protease inhibitor-based regimen and those who are non-natives to the study setting. Much as the third 90% of the global UNAIDS 90-90-90 target has been achieved, the national implementation of PMTCT guidelines should be tailored to its contextual needs.

 

Copyright © 2020 Napyo et al. Published by Global Health and Education Projects, Inc. This is an open-access article distributed under the terms of the Creative Commons Attribution License CC BY 4.0.

Downloads

Download data is not yet available.

Downloads

Publication History

Issue

Section

Original Article

License